Detection rate of > 99% for Trisomies 21, 18 und 13
PreviaTest – the NIPT at a fair and affordable price
Screens for more than 80 Microdeletion or Microduplikation syndromes
Non-Invasive Prenatal Test: From gestational week 11 onwards (10 weeks + 0 days)
Congratulations on your pregnancy!
Over 3.5 million women worldwide have already trusted our PreviaTest and its underlying technology. Together with one of the world’s largest providers of genetic testing, we would like to assist you during your pregnancy. Now we are pleased to also offer you a comprehensive screening at a reasonable price.
The non-invasive PreviaTest
PreviaTest screens for the three most common trisomy conditions present at birth, Down Syndrome, Edwards Syndrome and Patau Syndrome. Independent validation studies, including the world’s largest study on the use of NIPT in clinical practice in nearly 147,000 women, have shown an accuracy rate of over 99% for detection of these conditions and a very low false-positive rate of 0.05%*. This means that fewer women will undergo invasive diagnostic procedures such as amniocentesis or chorionic villus sampling, which carry a 1-2% risk of miscarriage. PreviaTest® is non-invasive and therefore poses no risk to the mother or baby.
Determining the gender of your baby is an option you can request at no extra charge.
The high accuracy of PreviaTest
Validation studies show a detection rate of 99.5% for Trisomies 21, 18 and 13. The underlying technology of PreviaTest has been validated with world’s largest study of the clinical performance of NIPT with data calculated from the outcomes of over 146,000 pregnancies**.
Learn more by using PreviaTest
The PreviaTest additionally screens for:
Additionally, incidental findings will be reported. In microdeletions / microduplications small pieces of a chromosome are missing or the same piece is found twice. Most microdeletions are very rare and the carriers of such microdeletions can have heterogenous phenotypes, depending on many factors. The most common microdeletion affects chromosome 22, the reason why it is called 22q11.2 Microdeletion Syndrome. The incidence rate is around 1 in 4,000 births.
With PreviaTest you can screen for most deletions and microdeletions as well as duplications and microduplications (currently over 80). It is estimated that deletions, microdeletions, duplications and microduplications occur in about 1 in every 1,000 newborns and that the incidence rate does not depend on the mother’s age. Frequent microdeletion syndromes include:
PreviaTest – From gestational week 11 onwards
PreviaTest is available for all pregnant women from gestational week 11 onwards (10 weeks + 0 days).
Under specific conditions applicable to the following:
You will usually get your PreviaTest report in 7-10 calendars days after the blood draw. The report can tell you if the there is a high or low risk that your baby is affected by a genetic syndrome. If the report shows a high risk, then invasive diagnostic testing is recommended.
Comprehensive Testing – favorable prices
Option 1 is available for twin pregnancies.
We express our recommendation of Ultrasound as an important part of prenatal care.
PreviaTest screens for fetal chromosomal aberrations. It complements the ultrasound of your physician and does not replace the ultrasound in any case.
Remember, it is always important to consult a qualified healthcare professional before taking any genetic test to make sure you fully understand the conditions being tested for. PreviaTest is a screening test: If the test result shows a high risk for a screened condition, it is recommended to have a diagnostic test for confirmation.
Please consider that non-invasive prenatal testing can be appropriate for you but at the same time unsuitable. Before having non-invasive prenatal testing, you should consult a qualified healthcare professional to make sure you fully understand all the relevant risks, diagnoses, therapy options and possible consequences and medical concerns.
PreviaTest corresponds to BGI’s NIFTY and NIFTYPro Test. Therefore, PreviaTest is certified by the following organisations:
Where can I get PreviaTest?
[*] Wei Wang et al.(2015), Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146 958 pregnancies, Journal of Ultrasound in Obstetrics and Gynecology.
[**] Samples were collected between Jan 2011 and Aug 2013. The study was published in the Journal of Ultrasound in Obstetrics and Gynecology. Data above are the combination of clinical study and laboratory calculation.
PreviaTest is offered by our partner laboratory BGI Health and is processed at by BGI in Hong Kong.
PreviaTest corresponds to the NIFTY Test technology. NIFTY is a registered trademark of BGI Health.
BGI is registered office is at: Co., Ltd. 16 Dai Fu Street, Tai Po, Hong Kong.
PreviaTest is a registerd trademark of Eluthia GmbH: Im Bosseldorn 30, 69126 Heidelberg, Germany.